Valvular heart disease in patients with Parkinson’s disease treated with pergolide. Course following treatment modifications

被引：0
作者：
D. Dupuy
J. P. Lesbre
P. Gérard
M. Andrejak
O. Godefroy
机构：
[1] (UMR CNRS 8160) Service de Neurologie,Dept. of Neurology and Laboratoire de Neurosciences Fonctionnelles
[2] Hôpital Nord,Dept. of Cardiology
[3] University Hospital,Dept. of Clinical Pharmacology
[4] University Hospital,undefined
来源：
Journal of Neurology | 2008年 / 255卷
关键词：
Parkinson’s disease; pergolide; valvular heart disease; echocardiography;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[21]   Reversible Hypotony and Choroidal Effusion Following the Use of Pergolide for Parkinson's Disease [J].
Andreatta, Walter ;
Shah, Peter .
SEMINARS IN OPHTHALMOLOGY, 2015, 30 (5-6) :423-425
[22]   Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide [J].
E. Růžička ;
H. Línková ;
M. Pěnička ;
O. Ulmanová ;
L. Nováková ;
J. Roth .
Journal of Neurology, 2007, 254 :1575-1578
[23]   Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide [J].
Ruzicka, Evzen ;
Linkova, Hana ;
Penicka, Martin ;
Ulmanova, Olga ;
Novakova, Lucie ;
Roth, Jan .
JOURNAL OF NEUROLOGY, 2007, 254 (11) :1575-1578
[24]   Plasma homocysteine levels in pergolide-treated Parkinson disease patients [J].
Özkan, S ;
Colak, Ö ;
Kutlu, C ;
Ertan, M ;
Alatas, Ö .
CLINICAL NEUROPHARMACOLOGY, 2004, 27 (04) :163-165
[25]   Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients [J].
Perez-Lloret, Santiago ;
Rey, Maria Veronica ;
Crispo, James ;
Krewski, Daniel ;
Lapeyre-Mestre, Marise ;
Montastruc, Jean-Louis ;
Rascol, Olivier .
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (03) :351-360
[26]   A prospective survey of patients with valvular heart disease in Europe:: The Euro Heart Survey on Valvular Heart Disease [J].
Iung, B ;
Baron, G ;
Butchart, EG ;
Delahaye, F ;
Gohlke-Bärwolf, C ;
Levang, OW ;
Tornos, P ;
Vanoverschelde, JL ;
Vermeer, F ;
Boersma, E ;
Ravaud, P ;
Vahanian, A .
EUROPEAN HEART JOURNAL, 2003, 24 (13) :1231-1243
[27]   High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias [J].
Storch, A ;
Trenkwalder, C ;
Oehlwein, C ;
Winkelmann, J ;
Polzer, U ;
Hundemer, HP ;
Schwarz, J .
PARKINSONISM & RELATED DISORDERS, 2005, 11 (06) :393-398
[28]   Comparative study of effects of bromocriptine and pergolide in Parkinson's disease [J].
deYebenes, JG ;
Ruiz, PJG ;
Pernaute, RS .
REVISTA DE NEUROLOGIA, 1997, 25 (145) :1343-1345
[29]   Pergolide versus levodopa monotherapy in early Parkinson's disease patients:: The PELMOPET study [J].
Oertel, WH ;
Wolters, E ;
Sampaio, C ;
Gimenez-Roldan, S ;
Bergamasco, B ;
Dujardin, M ;
Grosset, DG ;
Arnold, G ;
Leenders, KL ;
Hundemer, HP ;
Lledó, A ;
Wood, A ;
Frewer, P ;
Schwarz, J .
MOVEMENT DISORDERS, 2006, 21 (03) :343-353
[30]   Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review [J].
Steiger, Malcolm ;
Jost, W. ;
Grandas, F. ;
Van Camp, G. .
JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (02) :179-191
12345